Cargando…

Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer

BACKGROUND: Targeting regulatory T cell (Treg) infiltration is an emerging strategy for cancer immunotherapy. However, its efficacy in advanced prostate cancer remains unclear. Here, we showed the therapeutic efficacy of anti-Treg treatment in a canine model of advanced prostate cancer. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maeda, Shingo, Motegi, Tomoki, Iio, Aki, Kaji, Kenjiro, Goto-Koshino, Yuko, Eto, Shotaro, Ikeda, Namiko, Nakagawa, Takayuki, Nishimura, Ryohei, Yonezawa, Tomohiro, Momoi, Yasuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804701/ https://www.ncbi.nlm.nih.gov/pubmed/35131860 http://dx.doi.org/10.1136/jitc-2021-003731

Ejemplares similares

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
por: Maeda, Shingo, et al.
Publicado: (2022)

Detection of Canine Urothelial Carcinoma Cells in Urine Using 5-Aminolevulinic Acid
por: Kaji, Kenjiro, et al.
Publicado: (2022)

Effects of high-dose docosahexaenoic acid supplementation as an add-on therapy for canine idiopathic epilepsy: A pilot study
por: Yonezawa, Tomohiro, et al.
Publicado: (2023)

Clinical assessment of testosterone analogues for urethral sphincter mechanism incompetence in ten spayed female dogs
por: NISHI, Reo, et al.
Publicado: (2021)

Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
por: Van Damme, Helena, et al.
Publicado: (2021)

Detection of domestic cat hepadnavirus by next-generation sequencing and epidemiological survey in Japan
por: SAKAMOTO, Haruka, et al.
Publicado: (2023)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma
por: YOKOTA, Shohei, et al.
Publicado: (2022)

The impact of damage-associated molecules released from canine tumor cells on gene expression in macrophages
por: Eto, Shotaro, et al.
Publicado: (2021)

Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma
por: Yoshimoto, Sho, et al.
Publicado: (2019)

Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues
por: IKEDA, Namiko, et al.
Publicado: (2021)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-07. Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination with partial T(reg) depletion and double checkpoint blockade in children with relapsed high-grade gliomas.
por: Eyrich, Matthias, et al.
Publicado: (2022)

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma
por: YOSHIMOTO, Sho, et al.
Publicado: (2019)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer
por: YOSHIMOTO, Sho, et al.
Publicado: (2020)

PDPN Is Expressed in Various Types of Canine Tumors and Its Silencing Induces Apoptosis and Cell Cycle Arrest in Canine Malignant Melanoma
por: Shinada, Masahiro, et al.
Publicado: (2020)

Toceranib phosphate (Palladia) reverses type 1 diabetes by preserving islet function in mice
por: KISHI, Kazuhisa, et al.
Publicado: (2023)

ErbB2 copy number gain is associated with adverse outcome in canine mammary carcinoma
por: SAKAI, Kosei, et al.
Publicado: (2021)

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
por: Isoyama, Sho, et al.
Publicado: (2021)

Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan
por: Yoshida, Shino, et al.
Publicado: (2023)

Aberrant expression of the COX2/PGE(2) axis is induced by activation of the RAF/MEK/ERK pathway in BRAF(V595E) canine urothelial carcinoma
por: Yoshitake, Ryohei, et al.
Publicado: (2020)

Author Correction: Aberrant expression of the COX2/PGE(2) axis is induced by activation of the RAF/MEK/ERK pathway in BRAF(V595E) canine urothelial carcinoma
por: Yoshitake, Ryohei, et al.
Publicado: (2020)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer
por: Ward, S T, et al.
Publicado: (2015)

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
por: Anker, Jonathan, et al.
Publicado: (2023)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
por: Kato, Ryoji, et al.
Publicado: (2020)

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
por: Kobayashi, Tomoko, et al.
Publicado: (2020)

CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition
por: Kapur, Neeraj, et al.
Publicado: (2016)

Seroprevalence of antibodies against severe acute respiratory coronavirus 2 (SARS-CoV-2) in household dogs in Japan
por: ITO, Genta, et al.
Publicado: (2021)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_odtr4497avo4lsg4rmkn2efl3n